The purpose of the assessment is to evaluate Vorapaxar (ZONTIVITY™) for the reduction of cardiovascular events.
Final version of the assessment was published in June 2015
Below is the documentation provided by the Joint Assessment authoring team
Vorapaxar for the reduction of thrombotic cardivascular events_Rapid REA_Final_Jun 2015
This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.
©2021 EUnetHTA All rights reserved.
